Dr Rob Scott is currently the Chief Medical Officer at Abbvie with responsibility for around 40 new molecular entities, three thousand people and a budget of close to two billion dollars. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implementing clinical trials.

Rob is Zimbabwean born and a graduate of University of Cape Town. Rob has held leadership positions in global Pharma for over thirty years.. He began his industry career with J&J in South Africa. In 1992 he joined Pfizer and became the Global Therapeutic Head for CV and Metabolic, responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc.

In 2002, Rob became the Chief Medical Officer and Executive Vice President of R&D of AtheroGenics, an emerging Pharma company in Atlanta Georgia. While at AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech company. In 2008, he became the CMO and Head of Development of Cerenis Therapeutics in Toulouse, France. In 2010, he joined Amgen as the Global Therapeutic Area Head for Cardiovascular and Metabolic Development. At Amgen, he was responsible for accelerating the development of Repatha which was the first PCSK9 inhibitor to be submitted in Europe and the USA. He also successfully submitted Corlanor which was approved without a single US trial participant. In 2014, Dr Scott was also appointed as the head of a newly created Center of Excellence focused on using predictive analytics for designing and implementing clinical trials at Amgen, called the Development Design Center. In 2015, he took over the leadership of the Neuroscience, Bone, Nephrology and Inflammation Franchise.

Rob is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. He is a leader in digital transformation of clinical research.